A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ODESA
- 15 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016.
- 15 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016.
- 15 Jul 2016 Status changed from recruiting to active, no longer recruiting.